Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials

作     者：James J.Connolly Kohtaro Ooka Joseph K.Lim 

作者机构：Department of Internal MedicineYale University School of MedicineNew HavenCTUSA Division of GastroenterologyHepatology and NutritionUniversity of Pittsburgh Medical CenterPittsburghPAUSA Yale Liver CenterSection of Digestive DiseasesYale University School of MedicineNew HavenCTUSA 

出 版 物：《Journal of Clinical and Translational Hepatology》 (临床与转化肝病杂志（英文版）)

年 卷 期：2018年第6卷第3期

页      面：264-275页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Fatty liver Non-alcoholic steatohepatitis Clinical trials Pharmacotherapy Obeticholic acid 

摘      要：Non-alcoholic steatohepatitis(NASH)results from inflammation and hepatocyte injury in the setting of hepatic ***-alcoholic steatohepatitis increases the risk of progression to liver fibrosis and cirrhosis,and is the most rapidly growing etiology for liver failure and indication for liver transplantation in the *** loss and lifestyle modification remain the standard first-line treatment,as no USA Food and Drug Administration-approved pharmacotherapy currently *** past decade has seen an explosion of interest in drug development targeting pathologic pathways in non-alcoholic steatohepatitis,with numerous phase 2 and 3 trials currently in ***,we concisely review the major targets and mechanisms of action by class,summarize results from com-pleted pivotal phase 2 studies,and provide a detailed outline of key active studies with trial data for drugs in development,including obeticholic acid,elafibranor,cenicriviroc and selonsertib.